Drug
Pimavanserin clinical trials
Also written Nuplazid and ACP-103.
- studies test it
- 43
- open now
- 9
- in phase 3
- 15
- first study started
- 2004
Keep track of what changes. Save the pimavanserin studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
43 studies that test it; most in 2022 (5)
| Year | Studies |
|---|---|
| 2004 | 3 |
| 2005 | 1 |
| 2007 | 2 |
| 2008 | 1 |
| 2010 | 1 |
| 2013 | 1 |
| 2016 | 4 |
| 2017 | 3 |
| 2018 | 4 |
| 2019 | 3 |
| 2020 | 4 |
| 2022 | 5 |
| 2023 | 4 |
| 2024 | 3 |
| 2025 | 3 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 2
- Phase 1
- 2
- Phase 2
- 20
- Phase 3
- 15
- Phase 4
- 6
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 27 · Other 16
ACADIA Pharmaceuticals Inc. (25) · Baylor College of Medicine (2) · VA Office of Research and Development (2) · Tasly Pharmaceutical Group Co., Ltd (1) · University Hospital, Strasbourg, France (1) · Humanis Saglık Anonim Sirketi (1) · Joseph Jankovic (1) · National Institute of Neurological Disorders and Stroke (NINDS) (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses pimavanserin is read from its arms, and is right about nine times in ten.
Testing it · 43
- Psilocybin Efficacy With or Without Pimavanserin PretreatmentRecruitingPhase 1/2Johns Hopkins UniversityNCT07610135Written as Pimavanserin
- Pimavanserin for Rigid-compulsive Symptoms in Autism Spectrum DisorderRecruitingPhase 2New York State Psychiatric InstituteNCT05999240Written as Pimavanserin Tartrate 34 Mg ORAL CAPSULE [NUPLAZID]
- Pimavanserin vs. Quetiapine for Treatment of Parkinson's PsychosisRecruitingPhase 4VA Office of Research and DevelopmentNCT04373317Written as Pimavanserin
- Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative DiseasesRecruitingPhase 4Vanderbilt University Medical CenterNCT05357612Written as Pimavanserin
- Pimavanserin for Insomnia in Veterans With PTSDRecruitingPhase 2VA Office of Research and DevelopmentNCT05441280Written as pimavanserin
- Investigating the Neuropsychological Effects of 5-HT2a AntagonismRecruitingNot applicableUniversity of OxfordNCT07022366Written as Pimavanserin 10mg
- Comparing Antipsychotic Medications in LBD Over TimeRecruitingPhase 4The University of Texas Health Science Center at San AntonioNCT05590637Written as Pimavanserin
- Psilocybin With Pimavanserin Compared to Psilocybin Alone for the Treatment of Major Depressive DisorderRecruitingPhase 2Icahn School of Medicine at Mount SinaiNCT06592833Written as Pimavanserin
- Pimavanserin and Aggression and Social Cognition.RecruitingPhase 2Ohio State UniversityNCT05895513Written as Pimavanserin 34 mg
- A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease PsychosisCompletedPhase 3Tasly Pharmaceutical Group Co., LtdNCT06068465Written as pimavanserin tartrate
- Randomized Placebo Controlled Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease.CompletedPhase 2University Hospital, Strasbourg, FranceNCT03947216Written as Active drug: pimavanserin 17mg (2 strength tablets)
- Extension Study of Pimavanserin in Irritability Associated With Autism Spectrum DisorderTerminatedPhase 2/3ACADIA Pharmaceuticals Inc.NCT05555615Written as Pimavanserin
- Pimavanserin for the Treatment of Irritability Associated With Autism Spectrum DisorderCompletedPhase 2/3ACADIA Pharmaceuticals Inc.NCT05523895Written as Pimavanserin
- Extension Study of Pimavanserin for the Adjunctive Treatment of SchizophreniaTerminatedPhase 3ACADIA Pharmaceuticals Inc.NCT03121586Written as Pimavanserin
- Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of SchizophreniaCompletedPhase 3ACADIA Pharmaceuticals Inc.NCT04531982Written as Pimavanserin
- Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease PsychosisCompletedPhase 4ACADIA Pharmaceuticals Inc.NCT04292223Written as Pimavanserin
- A Safety Study of Pimavanserin in Adult and Elderly Subjects Experiencing Neuropsychiatric Symptoms Related to Neurodegenerative DiseaseCompletedPhase 3ACADIA Pharmaceuticals Inc.NCT03575052Written as Pimavanserin
- Extension Study of Pimavanserin in Adult Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative DiseaseCompletedPhase 3ACADIA Pharmaceuticals Inc.NCT03623321Written as Pimavanserin
- Pimavanserin for Sleep in Parkinson DiseaseWithdrawnEarly Phase 1State University of New York - Downstate Medical CenterNCT05796167Written as Pimavanserin
- The Sub-Sero StudyWithdrawnPhase 2Bjorn H. EbdrupNCT03994965Written as Pimavanserin 34 milligrams (MG) [Nuplazid]
See all 43 studies that test pimavanserin →
Given in every arm · 1 — pimavanserin is usual care beside what is tested
Codes
What other systems call pimavanserin · ClinicalTrials.gg INT004917
- MeSH (NLM) C510793pimavanserinConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) JZ963P0DIKPIMAVANSERINConfirmed FDA, NLM, Wikidata
- RxNorm 1791685Confirmed FDA, Wikidata
- Wikidata Q7194603pimavanserinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C76444PimavanserinOne source FDA
- DrugBank DB05316One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C510793 | pimavanserin | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | JZ963P0DIK | PIMAVANSERIN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1791685 | — | Confirmed FDA, Wikidata |
| Wikidata | Q7194603 | pimavanserin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C76444 | Pimavanserin | One source FDA |
| DrugBank | DB05316 | — | One source Wikidata |
Also registered as pimavanserin tartrate (UNII NA83F1SJSR · RxNorm 1791686).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.